cinclus pharma header stockholm

Investor relations

Cinclus Pharma

Investors

Cinclus Pharma is a Swedish clinical stage pharma company developing small molecules for the treatment of gastric acid related diseases. Our lead candidate linaprazan glurate is being developed for treatment of severe gastroesophageal reflux disease (GERD).

Financial calendar

Year-end report 2024 (Q4) 20 February 2025
Annual Report 2024 17 April 2025
Q1 Report 2025 20 May 2025
Annual General Meeting 2025 22 May 2025
Q2 Report 2025 20 August 2025
Q3 Report 2025 20 November 2025

See all

Latest pressreleases


See allSubscribe

Contact